Bibliography of Subcutaneous
Biologically Identical Pellet Hormone Therapy

1. Salmon U, et. al.: Use of estradiol subcutaneous pellets in humans. Science 1939,90:162.

2. Mishel, D: Clinical study of estrogenic therapy with pellet implantation. Am J Obstet-Gynecol 1941:41:1009.

3. Greenblatt, R: Indications for hormone pellets in the therapy of endocrine and gynaecological disorders. American J Obstet Gyn, 1949:57:294.

4. Studd, J: Estradiol and testosterone implants in the treatment of psychosexual problems in postmenopausal women. Br J Obstet Gynaecol 1977:84:314.

5. Thom, M, Studd, J, Oestorgen/testosterone implant therapy. In: Oestrogens and the Menopause. Edited by M. I. Whitehead & J.W. W. Studd. Abbott Labs, London, 1978: 85

6. "Oral preparations, unlike implants, also reduce liver metabolism of clotting factors and lipids" Elkik F., Gompel A., MTP Press 103-25

7. Lobo, R: Subdermal estradiol pellets following hysterectomy and oophorectomy. Am J Obstet Gynecol 1980:138:714.

8. Thom, M, et.al: Hormone implantation. Br. Med J 1980:1:848.

9. Thom, M, et. al: Hormone profiles in post-menopausal women after therapy with subcutaneous implants. Br J Obstet Gynaecol 1981:88:426. (View)

10. Brincat, M., et. al.: Subcutaneous hormone implants for the control of climacteric symptoms. Lancet 1984:1:16.

11. Burger, H, et. al.: The management of persistent menopausal symptoms with oestradiol-testosterone implants: clinical, lipid and hormone results. Maturitas 1984:6:351.

12. Cardoza, L, et. al.: The effects of subcutaneous hormone implants during climacteric. Maturitas 1984:5:177.

13. Farish, E, et. al.: The effects of hormone implants on serum lipoproteins and steroid hormones in bilaterally oophorectomised women. Acta Endocrinol (Copenh) 1984:106:116.

14. Barlow, D, et. al.: Long-term hormone implants therapy-hormonal and clinical effects. Obstet & Gynecol 1986:67:321. (View)

15. Burger, H, et. al.: Effect of combined implants of oestradiol and testosterone on libido in postmenopausal women. Br Med J 1987:294:936.

16. Notelovitz, M., et. al.: Metabolic and hormonal effects of 50 mgm 17 B Estradiol Implants in surgically menopausal women. Obstet-Gynecol 1987:70:749.

17. Greenblatt, R., et.al.: Indications for hormonal pellets in the therapy of gynecologic disorders. Am J Obstet-Gynecol 1988:159:1540.

18. Savvas, M., et. al.: Skeletal effects of oral oestrogen compared with subcutaneous oestrogen and testosterone in postmenopausal women. Br Med J 1988:279:331.

19. Stanczyk, F, et. al.: A randomized comparison of nonoral estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988:159:1540.

20. Studd, J, et. al.: The relationship between plasma estradiol and the increase in bone density in postmenopausal women after treatment with subcutaneous hormone implants. Am J Obstet Gynecol 1990:63:1474.

21. Savvas, M., et. al.: Increase in bone mass after one year of percutaneous oestradiol and testosterone implants in postmenopausal women who have previously received oral oestrogens. Br J Obstet Gynaecol 1992:99:757

22. Smith, RNJ; Studd, J.W.W. Recent Advances in Hormone Replacement Therapy, British Journal of Hospital Medicine 1993

23. Holland, E, et. al.: The effect of 25-mg percutaneous estradiol implants on the bone mass of postmenopausal women. Obstet Gynecol 1994:83:43.

24. Davis, S., et. al.: Testosterone enhances estradiol’s effects on postmenopausal bone density and sexuality. Maturitas 1995:21:227.

25. Handelsman, D, Androgen Delivery Systems: Testosterone Pellet Implants: Pharma Bio: 1986: 459:467

26. Natrajan, P.,et.al.: Estrogen replacement therapy in women with previous breast cancer: Presented at the Sixty-first Annual Meeting of The South Atlantic Association of Ob/Gyn, White Sulfur Springs, West Va, Jan. 23-26: 1999: (View)

27. Davis, S., et. al, Effects of estradiol with and without testosterone on body composition and relationships with lipids in postmenopausal women Menopause: The J No Am Meno Soc 2000: 395

28. Sands RH, S., et.al. The effect of hormone replacement therapy and route of administration on selected cardiovascular risk factors in post-menopausal women. Fam Pra GB: 2000 Vol. 17, No. 6

29. Cravioto, M, et.al.: Pharmacokenietics and Pharmacodynamics of 25-mg estroadiol implants in postmenopausal Mexican women. The J No Am Meno Soc 2001: Vol. 8. No. 5: 353:360

30. Pirwany, I.,et.al.: Supraphysiological concentrations of estradiol in menopausal women given repeated implant therapy do not adversely affect lipid profiles. European Soc Hum Rep Emb 2002: Vol.17,No.3 pp. 825:829